Month: August 2025

Q2 2025 net revenues increased 6.4% to $294 million, or 6.0% on a constant currency basis(1), compared to Q2 2024 Q2 2025 net income of $8 million or $0.03 per diluted share, compared to net income of $9 million or $0.03 per diluted share in Q2 2024 Q2 2025 Adjusted EBITDA(1) increased 9.8% to $151 million, or 9.5% on a constant currency basis, compared to Q2 2024 Q2 2025 Adjusted EPS(1) of $0.20, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.19 in Q2 2024 Raising both full-year 2025 net revenues outlook to 4.5% – 6.0% and Adjusted EBITDA outlook to 6.0% – 7.5%, on a constant currency basisCLEVELAND, Aug. 08, 2025 (GLOBE NEWSWIRE) — Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab...

Topline Tigris results expected to be released around mid-August 2025TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the second quarter and provided a corporate update. The second quarter of 2025 marked significant clinical and operational progress for Spectral. Following the completion of patient enrollment in the Tigris trial in April, the Company remains on track to report topline results in the third quarter. Tigris is a Phase III trial evaluating PMX for the treatment of endotoxic septic shock. The results of this pivotal study are expected to support the Company’s Premarket Approval (“PMA”) submission to the U.S. Food and Drug Administration...

MONTREAL, Aug. 08, 2025 (GLOBE NEWSWIRE) — Boralex Inc. (“Boralex” or the “Corporation”) (TSX: BLX) is pleased to report its results for the second quarter of 2025. HighlightsFinancial resultsLower EBITDA(A)1, operating income and net earnings in Q2-2025:Production up 14% (10% on a Combined1 basis)2 from Q2-2024 owing to a strong performance by operating assets in North America and the contribution of newly commissioned sites in Europe. Production was nevertheless 2% (9%) below anticipated production1 due to poor wind conditions in Europe and the United States. EBITDA(A) of $113 million ($145 million) in Q2-2025, down $17 million ($7 million) from Q2-2024, mainly due to lower prices of short-term power purchase contracts in France and, on a consolidated basis, to a reduced share in net losses (earnings) of joint ventures and...

MONACO, Aug. 08, 2025 (GLOBE NEWSWIRE) — Costamare Bulkers Holdings Limited (“Costamare Bulkers” or the “Company”) (NYSE: CMDB) today reported unaudited financial results for the six-month period ended June 30, 2025 (“H1 2025”). Costamare Bulkers had no operating activity during the first half of 2024 and remained a wholly-owned subsidiary of Costamare Inc. (“Costamare”), a New York Stock Exchange (the “NYSE”) listed company, until May 6, 2025, when it became an independent, publicly traded company on NYSE through a spin-off from Costamare. Starting with the earnings release for the third quarter and the nine-month period ended September 30, 2025, which will reflect the first full quarter of operations, we intend to include additional financial information and management discussion on Costamare Bulkers’ performance. Costamare Bulkers...

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant reversal of compensated cirrhosis (F4) due to MASH and corroborating the anti-fibrotic activity of EFX seen in patients with pre-cirrhotic (F2-F3) MASH Cash, cash equivalents and short and long-term marketable securities of $1,086.2 million at June 30, 2025 SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported second quarter financial results for the period ending June 30, 2025, and provided business updates. “In the second quarter...